GILD · News · 20261104N

Oncology Pipeline Expansion

GILEAD SCIENCES, INC. · 2026-11-04 · Importance 34 · Surprise 42

Gilead and BioNTech are collaborating on a global Phase 3 trial of BioNTech’s pumitamig combined with a Gilead antibody-drug conjugate. The first-line regimen is being tested in metastatic triple-negative breast cancer, an aggressive subtype with limited existing treatment options. The study advances a combination approach intended to address this unmet need.